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Abstract
VEGF is widely investigated for therapeutic angiogenesis, but while
short-term delivery is desirable for safety, it is insufficient for new
vessel persistence, jeopardizing efficacy. Here, we investigated
whether and how VEGF dose regulates nascent vessel stabilization,
to identify novel therapeutic targets. Monoclonal populations of
transduced myoblasts were used to homogeneously express speci-
fic VEGF doses in SCID mouse muscles. VEGF was abrogated after
10 and 17 days by Aflibercept treatment. Vascular stabilization
was fastest with low VEGF, but delayed or prevented by higher
doses, without affecting pericyte coverage. Rather, VEGF dose-
dependently inhibited endothelial Semaphorin3A expression,
thereby impairing recruitment of Neuropilin-1-expressing mono-
cytes (NEM), TGF-b1 production and endothelial SMAD2/3 activa-
tion. TGF-b1 further initiated a feedback loop stimulating
endothelial Semaphorin3A expression, thereby amplifying the
stabilizing signals. Blocking experiments showed that NEM recruit-
ment required endogenous Semaphorin3A and that TGF-b1 was
necessary to start the Semaphorin3A/NEM axis. Conversely,
Semaphorin3A treatment promoted NEM recruitment and vessel
stabilization despite high VEGF doses or transient adenoviral deliv-
ery. Therefore, VEGF inhibits the endothelial Semaphorin3A/NEM/
TGF-b1 paracrine axis and Semaphorin3A treatment accelerates
stabilization of VEGF-induced angiogenesis.
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Introduction
Atherosclerotic coronary and peripheral artery diseases remain
major causes of morbidity and mortality, despite optimal surgical
and medical therapies (Norgren et al, 2007; Go et al, 2014). An
attractive strategy to fill this unmet clinical need is therapeutic
angiogenesis, that is the growth of normal, stable, and functional
blood vessels by delivering specific factors to ischemic tissues,
whereby the robust expansion of microvascular networks promotes
the growth of collateral arteries (arteriogenesis) through increased
shear stress and retrograde signals along the vessel walls via inter-
cellular gap junctions (Rissanen et al, 2005; Pries et al, 2010).
Vascular endothelial growth factor-A (VEGF) is the master regulator
of vascular growth in both development and postnatal life, and it
represents the major molecular target for therapeutic angiogenesis
(Giacca & Zacchigna, 2012). However, VEGF therapeutic potential
depends on both its dose and duration of expression. In fact, uncon-
trolled and sustained VEGF expression, achieved by a variety of
gene therapy vectors (Isner et al, 1996; Pettersson et al, 2000;
Schwarz et al, 2000; Sundberg et al, 2001; Zacchigna et al, 2007;
Karvinen et al, 2011) or cell-based approaches (Springer et al, 1998;
Lee et al, 2000), can cause the growth of aberrant vascular struc-
tures and angioma-like tumors in both normal and ischemic tissues.
On the other hand, in vivo inducible systems (Dor et al, 2002;
Tafuro et al, 2009) and treatment with the blocking receptor-body
VEGF-TrapR1R2 (Aflibercept) (Ozawa et al, 2004) showed that VEGF
expression shorter than about 4 weeks is insufficient to stabilize
normal newly induced vessels, leading to their regression after stim-
ulus cessation, although dose-dependent kinetics were not investi-
gated. Therefore, there is a need to identify molecular targets to
accelerate vascular stabilization despite short-term VEGF delivery.
The best understood mechanism leading to stabilization of newly
induced vessels is maturation, that is their association with peri-
cytes, which suppress endothelial proliferation and provide survival
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signals such as Angiopoietin-1 (Ang-1) and low levels of localized
VEGF expression (Darland et al, 2003; Carmeliet & Jain, 2011).
While maturation is a morphological feature of new vessels (peri-
cyte association), stabilization is the functional property of persist-
ing independently of further VEGF stimulation (Dor et al, 2002;
Potente et al, 2011) and is a therapeutically relevant property defin-
ing the minimum necessary duration of VEGF delivery to achieve a
persistent increase in vascularity. Different populations of bone
marrow (BM)-derived mononuclear cells also are recruited to the
sites of VEGF-induced angiogenesis in adult tissues, where they do
not incorporate into the newly formed vessels (Ziegelhoeffer et al,
2004; Zentilin et al, 2006), but exert pro-angiogenic effects by
secreting paracrine factors (Grunewald et al, 2006; Korpisalo et al,
2008). In particular, a specific population of monocytes co-expressing
CD11b and the VEGF co-receptor Neuropilin-1 (NRP1), and
named therefore neuropilin-expressing monocytes (NEM), do not
stimulate endothelial proliferation and vascular growth, but specifi-
cally favor pericyte and smooth muscle cell recruitment during
VEGF-induced angiogenesis by secreting transforming growth
factor-b (TGF-b) and platelet-derived growth factor-BB (PDGF-BB)
(Zacchigna et al, 2008), leading also to normalization of tumor
vessels and inhibiting tumor growth (Carrer et al, 2012). However,
it is unknown whether monocytes may also directly regulate the
acquisition of VEGF-independence by newly induced endothelial
structures.
Here, we found that increasing doses of VEGF, in a therapeuti-
cally relevant range, negatively regulated vascular stabilization in a
dose-dependent fashion, without affecting pericyte recruitment and
maturation, but rather by directly inhibiting endothelial expression
of the NRP1 ligand Semaphorin3A (Sema3A) and the NEM/TGF-b1
paracrine axis. Further, treatment with recombinant Sema3A
counteracted the effects of increasing VEGF dose and accelerated
stabilization of VEGF-induced angiogenesis in the therapeutic target
tissue of skeletal muscle, enabling vessel persistence despite tran-
sient VEGF delivery by adenoviral vectors.
Results
Vascular stabilization is progressively impaired by increasing
VEGF doses
As we previously found that the therapeutic window of VEGF
overexpression is controlled by the dose of VEGF localized in the
microenvironment around each expressing cell (Ozawa et al, 2004;
von Degenfeld et al, 2006), to rigorously determine the role of
VEGF dose on the vascular stabilization kinetics we took advan-
tage of a unique and well-characterized platform, based on mono-
clonal populations of retrovirally transduced mouse myoblasts that
express specific VEGF164 doses, thereby ensuring homogeneous
microenvironmental levels (Ozawa et al, 2004; Misteli et al, 2010).
We selected three clones expressing increasing VEGF levels
in vitro, previously shown to induce either normal (low and
medium) or aberrant angiogenesis (high): V low = 11.0  0.4 ng/106
cells/day, V med = 61.0  2.9 ng/106 cells/day, and V high =
133.2  9.7 ng/106 cells/day. Populations were implanted into leg
skeletal muscles of adult SCID mice to avoid immunologic
response to myoblasts expressing xenogeneic LacZ protein (Misteli
et al, 2010). All clones engrafted with similar efficiency over the
first week after implantation, as determined by qRT–PCR quan-
tification of the genomically integrated b-gal retroviral copies
(Appendix Fig S1). Vessel stabilization was determined as the frac-
tion of newly induced vessels that was capable of surviving inde-
pendently of VEGF signaling, by quantifying the persisting vessel
length density (VLD) after systemic treatment with VEGF-TrapR1R2
(Aflibercept), a potent receptor-body shown to completely abrogate
VEGF signaling in vivo (Holash et al, 2002), or saline control. The
same VEGF-Trap dose was previously shown to efficiently abro-
gate all VEGF levels used here with the same myoblast-based plat-
form, whereas it did not affect pre-existing vessels in the absence
of VEGF overexpression (Ozawa et al, 2004). As expected, after 2
and 3 weeks, both low and medium VEGF levels yielded a
network of homogeneous capillaries, whereas high VEGF led to
aberrant angioma-like structures (Fig 1A). Muscle areas remote
from the site of myoblast implantation (as determined by X-gal
staining) in saline-treated mice were used as controls. The mean
VLD of pre-existing muscle capillaries in these areas was
15  0.7 mm/mm2 and the VLD increase above this value repre-
sents the amount of newly induced vessels. Trap treatment was
started 4 days before tissue harvest. Therefore, the effects
observed at the analysis time points of 2 and 3 weeks reflect the
stabilization achieved at the start of treatment, 10 and 17 days
after cell injection, respectively. After 10 days, 31  3.6% of the
vessels induced by low VEGF were already VEGF-independent,
whereas similarly normal vessels induced by medium VEGF
regressed completely, as well as the aberrant structures induced by
high VEGF, reducing VLD to a similar value as the pre-existing
capillary networks in control areas (Fig 1A and B). By 17 days,
the fraction of stabilized new vessels induced by low VEGF
increased to 49  3.5%, while 31  8.3% became VEGF-indepen-
dent with medium VEGF levels (Fig 1A and C). Aberrant vascular
structures induced by high VEGF were still completely sensitive to
VEGF deprivation. Therefore, increasing VEGF levels, within the
range that induces only normal angiogenesis, dose-dependently
impaired the stabilization of newly induced capillaries.
Stabilization rate does not correlate with differential pericyte
coverage or vascular perfusion
Both pericyte recruitment and establishment of functional flow
have been shown to provide crucial signals for the stabilization of
nascent vascular structures (Potente et al, 2011). Pericyte coverage
of newly induced vessels was quantified 2 weeks after implanta-
tion of the different clones in hind-limb muscles by measuring
their maturation index, that is, the ratio of the NG2-positive/CD31-
positive areas after immunofluorescence staining. As shown in
Fig 1A, the normal capillaries induced by both low and medium
VEGF were tightly associated with NG2-positive/a-SMA-negative
pericytes, with a similar maturation index (Vlow = 0.4  0.02 and
Vmed = 0.4  0.06, P = N.S.). As previously described (Ozawa
et al, 2004), aberrant structures induced by high VEGF were not
covered by pericytes, but rather by NG2-negative/a-SMA-positive
smooth muscle cells (Fig 1A), which have a different biological
function, providing structural support but not regulatory signals to
the endothelium, and therefore their maturation index could not
be quantified.
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Figure 1. VEGF impairs vascular stabilization despite similar pericyte coverage.
A Immunofluorescence staining of endothelium (CD31, in red), pericytes (NG2, in green), smooth muscle cells (a-SMA, in cyan), and nuclei (DAPI, in blue) on frozen
sections of limb muscles injected with myoblast clones expressing different VEGF levels (V Low, V Med, and V High, respectively) and treated with VEGF-Trap or
saline after 10 and 17 days. Analysis was performed after 4 days of treatment (2 and 3 weeks, respectively). All normal vessels induced by low and medium VEGF
doses displayed a similar coverage by normal pericytes, whereas aberrant structures induced by high VEGF were covered with a-SMA-positive smooth muscle cells.
Asterisks indicate muscle fibers, which were mostly sectioned in longitudinal orientation, although some cross sections are visible depending on the orientation of
muscle bundles. Scale bar = 25 lm.
B, C Quantification of vessel length density (VLD) on the same samples showed that stabilization started already by 10 days for vessels induced by low VEGF, but not
until 17 days for those induced by medium VEGF, despite similar pericyte coverage, while aberrant structures induced by high VEGF always regressed. Data
represent the mean  SEM of individual images (n) acquired from three muscles/group; 2 weeks (B): V Low saline, n = 9; V Med saline, n = 13; V High saline, n = 8;
V Low TRAP, n = 28; V Med TRAP, n = 22; V High TRAP, n = 30; 3 weeks (C): V Low saline, n = 9; V Med saline, n = 11; V High saline, n = 19; V Low TRAP, n = 43;
V Med TRAP, n = 14; V High TRAP, n = 19; *P < 0.05 and ***P < 0.001 (all versus Ctrl) by one-way ANOVA with Bonferroni multiple comparisons test; 2 weeks
(B): V Low TRAP versus Ctrl P < 0.0001; 3 weeks (C): V Low TRAP versus Ctrl P < 0.0001; V Med TRAP versus Ctrl P = 0.0158.
Source data are available online for this figure.
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The establishment of functional blood flow in newly induced
vascular structures was assessed by intravenous injection of fluores-
cently labeled tomato lectin, which binds to the luminal endothelial
surface of vessels only if they are perfused by the systemic circula-
tion (von Degenfeld et al, 2006). Both normal vessels and aberrant
structures induced by all VEGF doses were stained by lectin and
therefore functionally perfused (Fig EV1A). Further, quantification
of the ratio between lectin-positive and CD31-positive vessel lengths
did not show any significant difference among the groups
(Fig EV1B) and very few non-perfused endothelial structures
were visible in every condition with similar frequency. These
results suggest that neither differential pericyte recruitment nor
establishment of functional flow were responsible for the different
stabilization kinetics of normal vessels induced by low and medium
VEGF doses.
TGF-b1 and Sema3A are downregulated in tissues exposed to
increasing VEGF doses
To investigate the mechanism by which increasing VEGF doses
impaired the stabilization of similarly normal and pericyte-covered
capillaries, we quantified the expression of the main vascular matu-
ration and remodeling factors (PDGF-BB, Ang-1, Ang-2, and TGF-b1)
and of Sema3A. Sema3A is a secreted axon-guidance protein that
can be expressed by endothelial cells and, through binding to NRP1,
can recruit neuropilin1-expressing monocytes (NEM) (Zacchigna
et al, 2008), although its role in the stabilization of VEGF-induced
angiogenesis is unknown. Muscles were injected with the 3 VEGF-
expressing clones or control myoblasts and, since the differences in
vascular stabilization were detected already with VEGF-Trap treat-
ment starting 10 days after cell implantation, gene expression was
measured at day 7 in order to detect the most relevant differences
for the stabilization process. As shown in Fig 2A, Pdgfbb, Ang1, and
Ang2 were moderately upregulated in tissues exposed to low VEGF,
but their expression patterns with increasing VEGF doses did not
correlate with the observed decreasing trend in stabilization rates.
On the other hand, both Sema3a and Tgfb1 expression were robustly
increased 4- to 5-fold compared to control levels with low VEGF and
were significantly downregulated with higher VEGF doses. Gene
expression data were confirmed by immunostaining for Sema3A
protein on tissue sections, which showed a clear and progressive
reduction in Sema3A abundance down to control levels in the areas
of active angiogenesis by increasing VEGF doses (Fig 2B). Further,
the different myoblast populations all expressed similar levels of
Sema3a that were unrelated to the amount of VEGF, thereby exclud-
ing that the VEGF-expressing cells may be the source of the different
Sema3A amounts observed in vivo (Appendix Fig S2).
In order to verify whether Sema3A was produced by endothelium
or other populations, fluorescence in situ hybridization (FISH) was
performed to co-detect the mRNA for cd31 (marking endothelium)
and Sema3a on frozen sections of muscles implanted with V low
myoblasts at the 7-day time point, that is the condition displaying
the highest Sema3A expression. Areas of myoblast implantation
were identified by X-gal staining on adjacent serial sections and, as
shown in Fig 2C, the green signal from the Sema3a transcript was
detected mostly in cells that also expressed cd31 (yellow arrows),
whereas only rare cells were positive for either Sema3a or cd31
alone (green and red arrows, respectively). Quantification of the
number of cells expressing either or both transcripts showed that
86.4  1.7% of the endothelial cells expressed Sema3A and that
92.3  0.9% of the Sema3A-expressing cells was endothelial
(Fig 2D). Therefore, endothelium was the source of the greatest part
of Sema3A produced in the areas of active angiogenesis.
Increasing VEGF doses impair in vivo endothelial Sema3A
expression and NEM recruitment
Both VEGF and Sema3A are able to recruit NEM, which have been
shown to promote smooth muscle cell recruitment and arteriogene-
sis through paracrine factor secretion (Zacchigna et al, 2008). NEM
were previously shown to co-express NRP1 and the monocyte
marker CD11b (Zacchigna et al, 2008). Both immunostaining and
flow cytometry confirmed that essentially all CD11b+ cells recruited
to muscles implanted with VEGF-expressing clones also expressed
NRP1 (Fig EV2). Since NRP1 is also expressed on endothelium and
pericytes, for clarity in subsequent experiments NEM were identified
only by CD11b staining, as previously described (Zacchigna et al,
2008). One week after implantation of VEGF-expressing myoblasts,
increased numbers of CD11b+ cells were recruited to the areas of
active angiogenesis compared to controls. However, increasing
VEGF levels impaired NEM recruitment in a dose-dependent fashion
(Fig 3A), as confirmed by quantification of NEM frequency on
Figure 2. TGF-b1 and Sema3A are downregulated in vivo by increasing VEGF doses.
Muscles were harvested 7 days after implantation of V Low, V Med, and V High clones or control cells (Ctrl).
A Gene expression of Pdgfb, Ang1, Ang2, Tgfb1, and Sema3a was quantified by qRT-PCR and expressed as fold-change versus control muscles. Data represent individual
values, with mean  SEM (n = 3 or 4, as indicated); *P < 0.05 and **P < 0.01 by one-way ANOVA with Bonferroni multiple comparisons test, after data
normalization by logarithmic transformation. TGF-b1: V Low versus V Med P = 0.0047; V Low versus V High P = 0.0379; Sema3A: V Low versus V High P = 0.0042;
V Med versus V High P = 0.0179.
B Immunohistochemistry for Sema3A on frozen muscle sections confirmed a decreasing protein expression in the areas implanted with myoblasts producing increasing
VEGF doses (n = 4). The right panels represent higher-magnification views of the left panels, which encompass the majority of the implantation sites. Scale
bar = 50 lm.
C In situ hybridization for Sema3A (green) and CD31 (red) mRNA, with nuclei staining by DAPI, on frozen muscle sections. The three lower panels represent a higher-
magnification of the area in the white square in the top panel, as a merged image and as individual channels: arrows indicate cells expressing both transcripts
(yellow), only Sema3A (green), or only CD31 (red). Scale bar = 30 lm.
D Quantification of the percentage of endothelial cells (CD31+) that express Sema3A (left group) and of Sema3A-expressing cells that are endothelial (CD31+, right
group). Data represent the mean  SEM of 12 individual fields of view from three independent muscles (15–94 nuclei/image, 642 total nuclei). No statistics was
applied, as data represent complementary sets.
Source data are available online for this figure.
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histological sections in the different conditions (CD11b+ cells/cm of
vessel length; Fig 3B). In order to analyze cell-specific changes in
gene expression, CD31+ endothelial cells and CD11b+ NEM were
isolated ex vivo by FACS from implanted muscles. Flow cytometry
quantification confirmed the VEGF dose-dependent impairment in
NEM recruitment (Fig 3C). As shown in Fig 3D, isolated endothelial
cells downregulated Sema3a expression by 5-fold in a gradual and
VEGF dose-dependent fashion, similar to the results obtained from
whole-tissue analyses in Fig 2A, whereas neither Pdgfb nor Tgfb1
expression was regulated by VEGF dose. Isolated CD11b+ cells
expressed similar levels of both Nrp1 and Tgfb1 at all VEGF doses
(Fig 3D), but expressed two- to three-fold more Tgfb1 than endo-
thelial cells, again regardless of VEGF dose (Fig EV3). Taken together,
these results show that increasing VEGF doses specifically impaired
endothelial expression of Sema3a and NEM recruitment, but did not
regulate TGF-b1 expression by either endothelium or NEM, causing
a reduction in total TGF-b1 indirectly through inhibition of NEM
recruitment.
Endogenous Sema3A is required for NEM recruitment
The NRP1 receptor on NEM can bind both Sema3A and VEGF
(Zentilin et al, 2006; Zacchigna et al, 2008). To determine whether
Sema3A expression was required for NEM recruitment, we
performed loss-of-function experiments by systemic treatment with
an antibody that recognizes the CUB domains (a1a2) of NRP1 and
prevents its binding with Sema3A, but does not affect the interaction
with VEGF (anti-NRP1A, YW64.3) (Liang et al, 2007; Pan et al,
2007). Specific inhibition of Sema3A/NRP1 interaction essentially
abolished NEM recruitment in muscles injected with V Low and
V Med myoblasts, reducing the CD11b+ cell number to control
values (Fig 4A). The striking reduction was confirmed also after
normalizing for the induced vessel length (Fig 4B). As expected, anti-
NRP1A did not affect the amount of angiogenesis induced by the
different VEGF doses (Fig 4C). In agreement with the inhibition of
locally recruited NEM, gene expression analysis on total muscle
extracts showed that the upregulation of Tgfb1 caused by low VEGF
was abolished by inhibition of Sema3A/NRP1 binding (Fig 4D).
Interestingly, the amount of endogenous Sema3A protein in low
VEGF conditions, quantified by intensity of immunostaining on tissue
sections, was also significantly reduced, though not completely abol-
ished, by interference with Sema3A/NRP1 binding (Fig 4E). Taken
together, these data suggest that Sema3A signaling through NRP1 is
required for NEM recruitment and upregulation of TGF-b1 and,
partly, also of Sema3A itself at sites of VEGF-induced angiogenesis.
Increasing VEGF doses inhibit endothelial SMAD2/3 activation in
newly induced vessels
TGF-b1 can promote both endothelial activation and quiescence by
activating distinct intracellular signaling pathways through the
phosphorylation of the SMAD1/5 or SMAD2/3 complexes, respec-
tively (Goumans et al, 2002). Therefore, we determined whether
TGF-b signaling was differentially activated in tissues exposed to
increasing VEGF doses and which downstream pathway was prefer-
entially stimulated. As shown in Fig 5A, the expression of Id-1,
which is induced by the SMAD1/5 pathway and not by SMAD2/3
(Goumans et al, 2002), was not significantly increased in muscle
tissue 1 week after implantation of the different VEGF-expressing
clones compared to controls. Conversely, the expression of PAI-1,
which is induced by the SMAD2/3 pathway and not by SMAD1/5
(Goumans et al, 2002), was robustly increased about 10-fold in
tissues exposed to low VEGF levels compared to controls, but this
upregulation was abolished by higher VEGF doses. Immunofluores-
cence staining confirmed that SMAD2/3 was phosphorylated and
translocated into the endothelial nuclei of newly induced vessels
1 week after stimulation with low VEGF, but not with high VEGF
(Fig 5B). Therefore, the VEGF dose-dependent downregulation of
TGF-b1 expression specifically prevented the activation of the
SMAD2/3 pathway, which mediates endothelial stabilization, in
newly induced vascular structures.
Endothelial Sema3A expression is directly inhibited by VEGF and
induced by TGF-b1
In order to determine whether VEGF may regulate endothelial
Sema3A expression directly or indirectly, mouse aortic endothelial
cells were stimulated in vitro with increasing VEGF doses for 24 h
before RNA extraction and gene expression analysis. Increasing
VEGF doses directly downregulated endothelial expression of
Sema3a (Fig 6A), but did not affect that of Tgfb1 (Fig 6B), consis-
tently with the results obtained in ex vivo isolated endothelial cells.
Further, expression of the TGF-b1 downstream genes Pai1 and Id1
was not stimulated by any VEGF dose (Fig EV4A and B), whereas
both could be significantly upregulated by TGF-b1 treatment
(Fig EV4C and D). However, TGF-b1 directly and dose-dependently
upregulated endothelial Sema3a expression (Fig 6C). Therefore,
both VEGF and TGF-b1 signaling regulate endothelial Sema3A
expression, but with opposite effects.
These in vitro results raised the possibility that endothelial
Sema3A expression during VEGF-induced angiogenesis may be
Figure 3. Increasing VEGF doses inhibit NEM recruitment and endothelial Sema3A expression.
A Immunofluorescence staining of endothelial cells (CD31, in red) and NEM (CD11b, in green) on cryosections of limb muscles 1 week after injection with V Low, V Med,
and V High myoblast clones. Scale bar = 100 lm.
B Quantification of the number of NEM/cm of vessel length in sites of new angiogenesis by increasing VEGF doses. Data represent the mean  SEM of individual
images (n) acquired from three muscles/group: V Low, n = 48; V Med, n = 39; V High, n = 94; *P < 0.05 and ***P < 0.001 by one-way ANOVA with Bonferroni
multiple comparisons test: V Low versus V Med P = 0.0008; V Low versus V High P < 0.0001; V Med versus V High P = 0.0304.
C Endothelial cells (CD31+ quadrant) and NEM (CD11b+ quadrant) were sorted by FACS from muscles 1 week after injection with the same myoblast clones.
D Relative gene expression was quantified in the ex vivo FACS-purified endothelial cells (CD31+) and NEM (CD11b+) and expressed as fold-change versus the V High
group. Data represent individual values, with mean  SEM (n = 3–7, as indicated); **P < 0.01 by one-way ANOVA with Bonferroni multiple comparisons test, after
data normalization by logarithmic transformation; Sema3A: V Low versus V High P = 0.0157.
Source data are available online for this figure.
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Figure 4. Sema3A/NRP1 binding is required for NEM recruitment, TGF-b1 upregulation, and Sema3A production.
Mice, implanted with control cells (Ctrl) or myoblasts expressing low (V Low) or medium (V Med) VEGF levels, were treated with the anti-NRP1A antibody blocking Sema3A/
NRP1 binding (AbaNRP1A) or with control IgG2a. Analyses were performed after 1 week.
A, B Quantification of recruited NEM in sites of new angiogenesis by increasing VEGF doses, expressed as number of CD11b+ cells/mm2 of area (A) or /cm of vessel
length (B). Data represent the mean  SEM of individual images (n) acquired from three muscles/group. (A) Ctrl IgG2a, n = 11; Ctrl AbaNRP1A, n = 17; V Low IgG2a,
n = 24; V Low AbaNRP1A, n = 28; V Med IgG2a, n = 25; V Med AbaNRP1A, n = 34; *P < 0.05, **P < 0.01 and ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s
multiple comparisons test: V Low IgG2a versus Ctrl IgG2a P = 0.0068; V Low IgG2a versus V Low AbaNRP1A P = 0.0068; V Med IgG2a versus V Med AbaNRP1A
P = 0.0460. (B) V Low IgG2a versus V Low AbaNRP1A P < 0.0001; V Low IgG2a versus V Med IgG2a P = 0.0193; V Med IgG2a versus V Med AbaNRP1A P = 0.0046.
C Quantification of vessel length density generated by increasing VEGF doses after the different treatments. Data represent the mean  SEM of individual images (n)
acquired from three muscles/group: Ctrl IgG2a, n = 6; Ctrl AbaNRP1A, n = 6; V Low IgG2a, n = 19; V Low AbaNRP1A, n = 20; V Med IgG2a, n = 20; V Med AbaNRP1A,
n = 25; *P < 0.05, **P < 0.01 and ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s multiple comparisons test: V Low IgG2a versus Ctrl IgG2a P < 0.0001;
V Low AbaNRP1A versus Ctrl IgG2a P < 0.0001; V Low IgG2a versus V Med IgG2a P = 0.0014; V Low AbaNRP1A versus V Med AbaNRP1A P = 0.0179.
D Tgfb1 gene expression in total skeletal muscles after the different treatments, expressed as fold-change versus the Ctrl IgG2a group. Data represent individual
values, with mean  SEM (n = 3 or 4, as indicated); *P < 0.05 and **P < 0.01 by one-way ANOVA with Bonferroni multiple comparisons test, after data
normalization by logarithmic transformation; V Low IgG2a versus Ctrl IgG2a P = 0.0083; V Low IgG2a versus V Low AbaNRP1A P = 0.0315.
E Immunohistochemistry for Sema3A protein on frozen muscle sections with H&E counterstaining. The intensity of Sema3A stain was quantified as reciprocal
intensity on a scale out of 250. Scale bar = 100 lm. Data represent the mean  SEM of individual images (n) acquired from three muscles/group: No stain, n = 3;
Ctrl IgG2a, n = 23; Ctrl AbaNRP1A, n = 12; V Low IgG2a, n = 53; V Low AbaNRP1A, n = 38; *P < 0.05 and ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s
multiple comparisons test: V Low IgG2a versus No stain P = 0.0007; V Low IgG2a versus Ctrl IgG2a P < 0.0001; V Low AbaNRP1A versus Ctrl IgG2a P = 0.0142;
V Low IgG2a versus V Low AbaNRP1A P = 0.0001.
Source data are available online for this figure.
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actually induced by TGF-b1 rather than directly by VEGF. To
determine whether TGF-b1 was required for Sema3A induction
in vivo, we abrogated TGF-b1 signaling by systemic treatment
with a specific blocking antibody (Wan et al, 2008). TGF-b1
blockade essentially abolished the upregulation of Sema3A
production 1 week after implantation of V low myoblasts,
reducing it to the same level as controls (Fig 6D). Consistently
with the loss of Sema3A production, NEM recruitment by
low VEGF was also abolished (Fig 6E). Therefore, TGF-b1 is
required for the induction of Sema3A production by VEGF
in vivo.
Sema3A treatment promotes vascular stabilization without
inhibiting angiogenesis
Based on these results, we asked whether gain of function of
Sema3A signaling could reverse the impairment of vascular stabi-
lization caused by increasing VEGF doses. Therefore, animals were
treated with intramuscular injections of a recombinant Sema3A-Fc
fusion protein at two doses (0.1 and 10 mg/kg of average muscle
tissue weight) 4 and 6 days after implantation of V Low or V Med
myoblasts in the same muscles. Seven days after myoblast injec-
tion, Sema3A-Fc caused a dose-dependent increase in CD11b+ cell
recruitment at the sites of newly induced angiogenesis both in
the presence of low and medium VEGF. Interestingly, already
the lower dose (0.1 mg/kg) restored the NEM number in V Med
muscles to a similar level as in the untreated V Low tissues,
thereby abolishing the loss caused by the increasing VEGF
dose (Fig 7A). Since Sema3A may also inhibit angiogenesis
(Zacchigna et al, 2008; Maione et al, 2009), vessel length density
was quantified in treated muscles, showing that Sema3A-Fc
treatment at the doses used here did not affect the amount of
vascular growth induced by either low or medium VEGF levels
(Fig 7B).
To determine the functional effect of Sema3A delivery on
vascular stabilization, VEGF signaling was abrogated by systemic
treatment with VEGF-Trap and the resistant fraction of induced
vessels was calculated as the percentage of vessel length density
increase after Trap treatment compared to saline. Two weeks after
myoblast implantation, mice treated with control Fc protein showed
a vascular stabilization rate of 37  6% in the presence of low
VEGF, whereas vessels induced by medium VEGF doses completely
regressed, confirming the results shown in Fig 1. However, local
intramuscular treatment with 10 mg/kg of Sema3A-Fc caused the
early stabilization of 20  17% of vessels induced by medium VEGF
doses, as well as an increase in the resistant fraction of angiogenesis
induced by low VEGF to 60  11% (Fig 7C). These results suggest
that exogenous Sema3A can restore NEM recruitment and accelerate
vascular stabilization, which are impaired by increasing VEGF
doses.
Lastly, we sought to extend our findings, obtained with a
controlled myoblast-based gene delivery platform, to a gene deliv-
ery system appropriate for clinical translation as a gene therapy
approach. Therefore, we tested whether Sema3A treatment could
accelerate stabilization of angiogenesis induced by intramuscular
delivery of a VEGF-expressing adenoviral vector in immunocom-
petent C57/Bl6 mice. In this setting, the immune reaction against
the adenoviral vector eliminates the delivered gene within
A
B
Figure 5. Increasing VEGF doses inhibit activation of endothelial SMAD2/3.
A Relative gene expression of Id1, specifically induced by activated SMAD1/5,
and Pai1, specifically induced by activated SMAD2/3, in total muscle tissues
1 week after implantation with V Low-, V Med- and V High-expressing
myoblast clones or control cells (Ctrl), expressed as fold-change versus the
Ctrl group. Data represent individual values, with mean  SEM (n = 3 or 4,
as indicated); **P < 0.01 and ***P < 0.001 by one-way ANOVA with
Bonferroni multiple comparisons test, after data normalization by
logarithmic transformation; V Low versus Ctrl P = 0.0002; V Low versus
V Med P = 0.005; V Low versus V High P = 0.0016.
B Immunofluorescence staining of endothelium (CD31, in red), nuclei (DAPI,
in blue), and phosphorylated SMAD2/3 (in cyan) on cryosections of similarly
injected muscles confirmed that endothelial SMAD2/3 activation was
inhibited by increasing VEGF doses. Scale bar = 10 lm; n = 3.
Source data are available online for this figure.
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Figure 6. TGF-b1 regulates Sema3A production and NEM recruitment.
A–C Endothelial Sema3A expression is directly inhibited by VEGF and stimulated by TGF-b1 in vitro. Mouse aortic endothelial cells were stimulated with increasing
doses of recombinant VEGF164 or TGF-b1 for 24 h. The expression of Sema3a and Tgfb1 was quantified by qRT-PCR and expressed as fold-change versus the non-
stimulated cells. VEGF dose dependently inhibited Sema3a expression (A), but did not affect that of Tgfb1 (B), while TGF-b1 upregulated Sema3a expression in a
dose-dependent fashion (C). Data represent individual values, with mean  SEM (n = 4); **P < 0.01 and ***P < 0.001 by one-way ANOVA with Bonferroni multiple
comparisons test, after data normalization by logarithmic transformation; Sema3A expression upon VEGF stimulation: 40 versus 0 P = 0.0041; TGF-b1 upon VEGF
stimulation: no significant differences; Sema3A expression upon TGF-b1 stimulation: 1 versus 0 P < 0.0001; 2.5 versus 0 P < 0.0001; 40 versus 0 P < 0.0001.
D, E Inhibition of TGF-b1 abolishes Sema3A production and NEM recruitment in vivo. Mice, implanted with control cells (Ctrl) or myoblasts expressing low (V Low) VEGF
levels, were treated with a TGF-b1 blocking antibody. Analyses were preformed after 1 week. (D) Immunohistochemistry for Sema3A protein on frozen muscle
sections with H&E counterstaining. The intensity of Sema3A stain was quantified as reciprocal intensity on a scale out of 250. Scale bar = 50 lm. Data represent
the mean  SEM of individual images (n) acquired from three muscles/group: No stain, n = 10; Ctrl IgG1, n = 17; Ctrl AbaTGF-b1, n = 16; V Low IgG1, n = 23;
V Low AbaTGF-b1, n = 28. **P < 0.01 and ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s multiple comparisons test: V Low IgG1 versus No stain P = 0.0069;
V Low IgG1 versus Ctrl IgG1 P < 0.0001; V Low AbaTGF-b1 versus V Low IgG1 P = 0.0002. (E) Quantification of recruited NEM (number of CD11b+ cells/mm2 of
area). Scale bar = 25 lm. Data represent the mean  SEM of individual images (n) acquired from three muscles/group: Ctrl IgG1, n = 20; Ctrl AbaTGF-b1, n = 19;
V Low IgG1, n = 20; V Low AbaTGF-b1, n = 27; ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s multiple comparisons test: V Low IgG1 versus Ctrl IgG1
P = 0.0005; V Low AbaTGF-b1 versus V Low IgG1 P < 0.0001.
Source data are available online for this figure.
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10 days (Dai et al, 1995), causing transient VEGF expression of
insufficient duration to allow stabilization and persistence of
newly induced vessels, similar to a clinical scenario with
immunologically normal patients. Limb muscles of C57/Bl6 mice
were injected with 1 × 108 infectious units of an adenovirus
expressing murine VEGF164 linked to a truncated form of CD8 as
a cell-surface marker (AdVIC) or CD8 alone as a control (AdCD8).
In the absence of treatment, 1 week after delivery, Ad-VEGF
induced robust angiogenesis compared to the control vector and
caused a 2-fold increase in vessel length density (Fig 7D and E),
showing the initial efficacy of VEGF gene delivery. As expected, by
3 weeks, newly induced vessels had almost completely regressed in
muscles treated with control Fc protein, yielding a VLD similar to
uninjected control muscles that received no viral vector (Fig 7D
and E). However, local treatment with two intramuscular doses of
Sema3A-Fc on days 4 and 6 after adenoviral delivery caused
complete stabilization of induced angiogenesis and its persistence
by 3 weeks, maintaining VLD at the same level as after 1 week
(Fig 7D and E). Further, treatment with Sema3A led to an increased
NEM recruitment still after 3 weeks, compared to control Fc
protein, even though treatment was stopped 2 weeks earlier
(Fig 7F).
A
D
E F
B C
Figure 7.
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Discussion
Here, we uncovered a novel function for Neuropilin-1-expressing
monocytes to promote VEGF-independence of nascent blood
vessels. Further, NEM recruitment during VEGF-induced angiogene-
sis requires Sema3A upregulation and inhibition of the endothelial
Sema3A/NEM/TGF-b1 axis is a mechanism by which VEGF impairs
vascular stabilization without affecting vascular maturation (peri-
cyte recruitment). This impairment is VEGF dose-dependent and is
caused by VEGF levels within the range that induces only normal
and mature capillary networks and that is required for therapeutic
benefit (Ozawa et al, 2004; von Degenfeld et al, 2006). Conversely,
treatment with recombinant Sema3A counteracts the effects of
increasing VEGF levels, restores NEM recruitment, and accelerates
vascular stabilization, leading to persistent angiogenesis despite
transient VEGF delivery.
Taken together, our in vivo and in vitro results suggest a model
for the VEGF dose-dependent regulation of vascular stabilization
(Fig 8): (i) in the presence of low VEGF levels, activated endothelial
cells robustly express Sema3A, which recruits large numbers of
NEM that in turn lead to high levels of TGF-b1 in the tissue. TGF-b1
not only activates SMAD2/3 signaling in endothelial cells, known to
induce endothelial quiescence and vessel stabilization, but also
stimulates them to express further Sema3A, thereby providing a
positive feedback loop to maintain the stabilizing signals. The func-
tion of this feedback mechanism is shown by the fact that a) block-
ade of Sema3A/NRP1 binding not only inhibited NEM recruitment
and TGF-b1 expression, but also downregulated Sema3A itself
(Fig 4), suggesting that NEM recruitment contributes to sustaining
endothelial Sema3A production, and b) direct blockade of TGF-b1
abolished both Sema3A production and NEM recruitment despite
VEGF expression at low levels (Fig 6D and E); (ii) on the other
hand, higher levels of VEGF directly inhibit endothelial expression
of Sema3A and lead to the reversal of these events, resulting in
delayed stabilization of the newly induced vessels, despite pericyte
coverage being unaffected.
Lack of pericyte coverage in the early stages of physiological
angiogenesis (Benjamin et al, 1998) or in aberrant vascular structures
induced by excessive VEGF (Dor et al, 2002; Ozawa et al, 2004)
defines a plasticity window, whereby newly induced vessels are
unstable and can regress. However, it is unclear whether pericytes
are sufficient to prevent vessel regression. In fact, pericyte associa-
tion showed a protecting role on vascular persistence in the retina
under hyperoxic conditions and in tumors after VEGF withdrawal
(Benjamin et al, 1998; Helfrich et al, 2010), but vessel regression
after VEGF blockade has been described also for pericyte-covered
vessels (Inai et al, 2004; von Tell et al, 2006). In agreement with
the latter, we found that all normal capillaries induced by low and
medium VEGF levels were similarly covered by pericytes by
Figure 7. Sema3A restores NEM recruitment and accelerates vascular stabilization, without affecting the amount of induced angiogenesis.
A–C Mice, implanted with myoblasts expressing low (V Low) or medium (V Med) VEGF levels, were treated on days 4 and 6 after cell implantation with intramuscular
injections of Sema3A-Fc (0.1 or 10 mg/kg of average muscle tissue weight), or with control Fc protein. (A) Quantification of the number of NEM/cm of vessel length
in sites of new angiogenesis after 1 week. Data represent the mean  SEM of individual images (n) acquired from 3 to 5 muscles/group: V Low Fc, n = 21; V Low
0.1 mg/kg, n = 22; V Low 10 mg/kg, n = 28; V Med Fc, n = 20; V Med 0.1 mg/kg, n = 30; V Med 10 mg/kg, n = 25; **P < 0.01 and ***P < 0.001 by Kruskal–Wallis
analysis with Dunn’s multiple comparisons test: V Low Fc versus V Low 10 mg/kg P = 0.0027; V Med Fc versus V Med 0.1 mg/kg P = 0.001; V Med Fc versus V Med
10 mg/kg P < 0.0001. (B) Quantification of vessel length density (VLD) in treated muscles after 1 week. Data represent the mean  SEM of individual images (n)
acquired from 3 to 4 muscles/group: V Low Fc, n = 8; V Low 0.1 mg/kg, n = 20; V Low 10 mg/kg, n = 18; V Med Fc, n = 8; V Med 0.1 mg/kg, n = 23; and V Med
10 mg/kg, n = 27. Data were subjected to Kruskal–Wallis analysis with Dunn’s multiple comparisons test, and no significant differences were detected. (C) Vascular
stabilization rate was determined 2 weeks after cell implantation by measuring vessel length density after abrogation of VEGF signaling by VEGF-Trap. Treatment
with 10 mg/kg Sema3A-Fc did not affect the stabilization of angiogenesis induced by low VEGF, but significantly increased the resistant fraction of vessels induced
by medium VEGF. Data represent the mean  SEM of individual images (n) acquired from 3 to 4 muscles/group: V Low Fc, n = 32; V Low Sema3A, n = 14; V Med
Fc, n = 28; V Med Sema3A, n = 33; *P < 0.05 by one-way ANOVA with Bonferroni multiple comparisons test: V Med Fc versus V Med Sema3A P = 0.0458.
D–F Mice received intramuscular injections of adenovirus expressing VEGF (AdVIC) or CD8 control (AdCD8) and were treated on days 4 and 6 after vector delivery with
intramuscular injections of Sema3A-Fc (10 mg/kg of average muscle tissue weight) or control Fc protein. (D) Immunofluorescence staining of endothelium (CD31, in
red), pericytes (NG2, in green), smooth muscle cells (a-SMA, in cyan), and nuclei (DAPI, in blue), showing vessel density and morphology 1 week after injection of
adenoviral vectors alone (no treatment) or after 3 weeks and with Fc or Sema3A-Fc treatment. Scale bar = 50 lm. (E) Quantification of vessel length density (VLD)
on the same samples shows that treatment with Sema3A-Fc accelerated stabilization of vessels induced by transient and uncontrolled VEGF expression. Data
represent the mean  SEM of individual images (n) acquired from 3 to 4 muscles/group: Uninjected muscles, n = 72; AdCD8 1 week, n = 68; AdVIC 1 week, n = 53;
AdVIC+Fc 3 weeks, n = 78; AdVIC+Sema3AFc 3 weeks, n = 91; **P < 0.01 and ***P < 0.001 by Kruskal–Wallis analysis with Dunn’s multiple comparisons test:
AdCD8 1 week versus AdVIC+Fc 3 weeks P = 0.0037; all other comparisons indicated P < 0.0001. (F) Immunofluorescence staining of endothelial cells (CD31, in red)
and NEM (CD11b, in green) on frozen sections of muscles 3 weeks after injection of adenoviral vectors and with Fc or Sema3A-Fc treatment. White arrows indicate
NEM. Scale bar = 50 lm.
Source data are available online for this figure.
Figure 8. Working model for the VEGF dose-dependent regulation of
vascular stabilization.
CD11b+/NP-1+ = CD11b- and Neuropilin1-expressing monocytes; pSMAD2/3 =
phosphorylated SMAD2/3.
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2 weeks, but stabilization was still incomplete and further increased
by 3 weeks, with the medium VEGF condition lagging behind low
VEGF. Therefore, although pericyte recruitment is necessary,
complete stabilization requires further steps that are independent of
pericytes and can be impaired by increasing VEGF doses. Our
in vivo and in vitro data suggest that the axis between endothelial
Sema3A expression, NEM recruitment, and TGF-b1-induced phos-
phorylation of endothelial SMAD2/3 is such a mechanism.
On the other hand, aberrant structures induced by high VEGF
always regressed after TRAP treatment, but they lacked pericytes
and were coated by smooth muscle cells instead. Macro-vascular
smooth muscle cells have distinct biological functions from capillary
pericytes, providing mainly mechanical support rather than the
complex molecular cross-talk of regulatory signals that pericytes
exchange with endothelium (Jain, 2003). Further, although smooth
muscle-coated normal arteries and veins are physiologically stable,
the similarly smooth muscle-coated structures induced by high
VEGF are functionally aberrant, as they grow progressively and
behave as arterio-venous shunts (Zacchigna et al, 2007).
NEM have been described to produce paracrine factors capable
of attracting smooth muscle cells in vitro (Carrer et al, 2012).
However, it is unlikely that chemoattractant factors produced by
NEM may be responsible for the observed switch in mural cell
coverage between VEGF doses, as the condition where vascular
structures acquire a smooth muscle coat (high VEGF) corresponds
to the minimum amount of NEM recruitment (Fig 3). On the other
hand, we have found before that, while low VEGF levels allow peri-
cyte retention on the remodeling vessels, high VEGF levels cause
pericytes to disappear in the early stages of vessel activation
(Gianni-Barrera et al, 2013), consistently with the described anti-
pericyte effect of VEGF through the formation of non-functional
VEGF-R2/PDGF-Rb heterodimers (Greenberg et al, 2008). The origin
of smooth muscle cells that subsequently cover aberrant angioma-
like structures induced in these conditions is currently unknown.
Blood flow and shear stress also can provide stabilizing signals
to nascent vessels (Chen et al, 2012). However, available evidence
suggests that these factors may not play a role in the observed
impairment in vascular stabilization by VEGF dose. In fact, (i) the
vascular networks induced by the different VEGF doses were simi-
larly connected with the systemic circulation (Fig EV1); and (ii) we
previously found that the amount of blood flow in vessels induced
by the V Med myoblasts is actually higher than in those generated
by low VEGF (von Degenfeld et al, 2006), despite showing here that
stabilization is faster in the latter condition.
TGF-b receptor/SMAD signaling has been also involved in the
process of endothelial to mesenchymal transition (EndMT): for
example, spontaneous activation both of SMAD and non-SMAD
TGF-b signaling in the endothelium of PAI-1-deficient animals led to
EndMT and cardiac fibrosis (Ghosh et al, 2010; van Meeteren & ten
Dijke, 2012). Interestingly, we found the highest upregulation of
PAI-1 expression during angiogenesis induced by low VEGF, which
caused the fastest stabilization rate with strong TGF-b1 expression
and SMAD2/3 activation. Further, we could not detect any endothe-
lial cell co-expressing a-SMA and CD31, suggesting that TGF-b1
expression did not lead to EndMT during low VEGF-induced angio-
genesis. In fact, the pleiotropic effects of TGF-b1 signaling depend
on the specific set of activated downstream transcription factors
and selective SMAD2/3 activation, which we found in low VEGF
conditions, specifically promotes vessel stabilization by inhibiting
endothelial migration and proliferation that are instead required for
EndMT (Goumans et al, 2002; van Meeteren & ten Dijke, 2012).
Indeed, it has been shown that TGF-b1 stimulation of endothelial
proliferation or quiescence through Alk1 and Alk5, respectively,
depends on its dose: in fact, Alk1 is preferentially activated by low
TGF-b1, whereas at higher doses Alk5 becomes prevalent (Goumans
et al, 2002), consistently with our findings, where the most rapid
stabilization is caused by the highest TGF-b1 upregulation. Further,
PAI-1, which is induced by TGF-b1 activation of the Alk5 and
SMAD2/3 pathway, contributes to vessel stabilization by preventing
degradation of the provisional matrix deposited around new vessels
and favoring the establishment of new basal lamina (Potente et al,
2011), again consistently with our finding that PAI-1 was specifi-
cally and robustly induced in the low VEGF conditions, leading to
the fastest stabilization.
To our knowledge, these results provide the first evidence that
NEM recruitment to sites of VEGF-induced angiogenesis requires
Sema3A and that endothelial production of Sema3A is regulated,
with opposing effects, by VEGF and TGF-b1. It remains to be
completely elucidated by which mechanism Sema3A is initially
upregulated upon endothelial activation. However, our in vitro and
in vivo data suggest that this is not a direct effect of VEGF itself, and
strongly implicate a role for TGF-b1. In fact, in vitro VEGF treatment
did not increase basal Sema3A expression of cultured EC, whereas
TGF-b1 could do so robustly (Fig 6), and in vivo treatment with a
blocking antibody showed that TGF-b1 is required for Sema3A
expression upon VEGF delivery. Interestingly, recent data in a
model of liver regeneration show that endothelial expression of
TGF-b1 is stimulated by autocrine Ang-2 signaling (Hu et al, 2014).
These findings, together with our data on the role of TGF-b1,
suggest an explanation for the dual behavior of Sema3A expression
at different VEGF doses. In fact, upon angiogenic activation by
VEGF, endothelial cells release Ang-2 (Augustin et al, 2009), but we
found here that endothelial Ang-2 expression does not increase with
higher VEGF doses (Fig 2A). Therefore, it is possible to speculate
that, in low VEGF conditions, initial Ang-2 release upregulates
endothelial TGF-b1, which in turn stimulates Sema3A expression
and initiates the NEM/TGF-b1 positive feedback loop described
above, leading to sustained Sema3A production by NEM-produced
TGF-b1. However, as VEGF dose increases, Ang-2 expression is not
changed (Fig 2A) and the direct inhibition of Sema3A expression by
VEGF may become prevalent, leading to the reversal of the NEM/
TGF-b1 axis. Testing of this hypothesis will require ad hoc experi-
ments with pharmacologic blockade or genetic deficiency of Ang-2.
The direct effects of Sema3A on endothelium have been also
shown to inhibit VEGF-induced angiogenesis (Zacchigna et al, 2008;
Maione et al, 2009), both through competition for the shared recep-
tor NRP1 (Miao et al, 1999) and by inducing endothelial production
of a decoy VEGF receptor, soluble Flt-1 (Zygmunt et al, 2011).
However, we did not observe any such effect. In fact, 2 weeks after
cell injection, low VEGF, which is the condition with the highest
amount of Sema3A expression, induced a greater amount of vascular
growth than both medium and high doses, which instead caused
significant Sema3A downregulation (Fig 1B). This apparent discrep-
ancy may reflect a key role for the ratio between VEGF and Sema3A
doses. In fact, when overexpressed at much greater than physiologi-
cal levels through adeno-associated virus (AAV) vectors, Sema3A
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has been found to inhibit angiogenesis both by similarly over-
expressed VEGF in AAV-treated muscles (Zacchigna et al, 2008) and
by lower endogenous VEGF levels in tumor models (Maione et al,
2009, 2012). On the other hand, also endogenous levels of Sema3A
have been shown to restrain angiogenesis induced by endogenous
VEGF levels in tumors (Maione et al, 2009). However, in our work,
VEGF was overexpressed through constitutive retroviral vectors in
transduced myoblast populations, which were previously shown to
generate tissue levels of VEGF several fold higher than the maximum
induced by ischemia (von Degenfeld et al, 2006), whereas Sema3A
was not overexpressed and was regulated from the endogenous
promoter. In agreement with our data, previous results obtained
with different ratios of Sema3A- and VEGF-expressing AAV showed
that the anti-angiogenic effect was lost at a Sema3A:VEGF vector
ratio of 1:100, whereas NEM recruitment was still effectively
increased (Zacchigna et al, 2008). Taken together, these results
suggest that the anti-angiogenic effect of Sema3A depends on its rela-
tive dose to VEGF and can be overcome by a sufficient amount of
VEGF, while the NEM-recruiting function of Sema3A is active even
at very low doses.
In conclusion, our results show that increasing VEGF doses
impair vessel stabilization by directly inhibiting the Sema3A/NEM/
TGF-b1 axis, while treatment with recombinant Sema3A-Fc restores
NEM recruitment and accelerates vascular stabilization, without
inhibiting vascular growth and despite transient VEGF expression
by clinically relevant adenoviral vectors. This finding has implica-
tions for the design of safe and effective approaches for therapeutic
angiogenesis. In fact, we have previously found that VEGF doses
within the range inducing only normal angiogenesis are not thera-
peutically equivalent (von Degenfeld et al, 2006). In particular, the
lower doses, which we found here to allow the fastest stabilization,
are not effective to restore blood flow in ischemia, whereas func-
tional improvement requires higher doses, which induce similarly
normal vessels, but of larger size, and promote effective collateral
arteriogenesis (von Degenfeld et al, 2006), but also inhibit Sema3A
expression and delay stabilization. Furthermore, prolonged VEGF
expression raises safety concerns, but, while transient delivery is
desirable, it is insufficient to achieve effective stabilization and
persistence of the induced vessels. However, based on our findings,
co-delivery of Sema3A represents a promising target to accelerate
stabilization of micro-vascular networks induced by therapeutic
doses of VEGF, thereby enabling short-term and safer therapeutic
approaches without compromising efficacy.
Materials and Methods
Cell culture
Primary myoblasts isolated from C57BL/6 mice, already transduced
to express the b-galactosidase marker gene (lacZ), were further
infected at high efficiency (Springer & Blau, 1997) with retroviruses
carrying the cDNA of murine VEGF164 linked through an Internal
Ribosome Entry Sequence (IRES) to a truncated murine CD8a as
a FACS-sortable marker (Misteli et al, 2010). Early-passage myoblast
clones were isolated using a FACS Vantage SE cell sorter (Becton–
Dickinson, Basel, Switzerland) as described (Misteli et al, 2010). All
myoblast populations were cultured in 5% CO2 on collagen-coated
dishes, with a growth medium consisting of 40% F10, 40% DMEM
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany), and 20%
fetal bovine serum (HyClone, Logan, UT), supplemented with
2.5 ng/ml FGF-2 (R&D Systems, Abingdon, UK), as described (Banfi
et al, 2002).
VEGF164 ELISA measurements
The production of VEGF164 in cell culture supernatants was quanti-
fied using a Quantikine mouse VEGF Immunoassay ELISA kit (R&D
Systems Europe, Abingdon, UK). 1 ml of medium was harvested
from myoblasts in one 60-mm dish, following a 4-h incubation,
filtered, and analyzed in duplicate. Results were normalized by the
number of cells in the dish and time of exposure to medium. Four
dishes of cells were assayed per cell type (n = 4).
In vivo implantation of myoblasts
Six- to twelve-week-old immunodeficient SCID CB17 mice (Charles
River Laboratories, Sulzfeld, Germany) were used to avoid any
immunologic response to myoblasts expressing xenogenic LacZ
protein. Myoblasts were dissociated in trypsin and resuspended at a
concentration of 108 cells/ml in sterile PBS with 0.5% BSA (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany), and 106 myoblasts
were injected into the Tibialis anterior and Gastrocnemius muscles
in the lower hind limb, using a syringe with a 29.5-gauge needle, as
previously described (Ozawa et al, 2004). All experiments were
performed with similar number of samples from both muscle loca-
tions, and the results were pooled together.
Recombinant adenovirus production and in vivo implantation
Recombinant adenoviruses expressing mouse VEGF164 were
produced using the Adeno-XTM Expression System (Clontech, Saint-
Germain-en-Laye, France) according to the manufacturer’s recom-
mendations. Constructs also expressed a truncated version of CD8
as a cell surface marker, as previously described (Banfi et al, 2012).
Briefly, target genes were cloned into the pShuttle vector, sub-
cloned into the Adeno-X viral DNA, and used to transfect HEK293
cells with Fugene HD reagent (Roche Applied Science, Basel,
Switzerland). After 1 week, viral particles were collected from trans-
fected cells by repeated freezing–thawing and used for re-infection
of fresh HEK293. After 4–5 lysis and infection cycles, viral particles
were collected and purified by a double cesium chloride gradient.
Viral titer was determined as infectious units after serial infection of
HEK293 cells at different multiplicities of infection, as previously
described (Gueret et al, 2002). Adenoviral vectors were diluted in
physiological solution and injected in Tibialis anterior and
Gastrocnemius muscles in the lower hind limb of immunocompetent
C57/Bl6 mice at the titer of 1 × 108 infectious units/injection, with a
29.5-gauge needle syringe.
VEGF-TrapR1R2 treatment
Mice were treated with 25 mg/kg of VEGF-TrapR1R2 (Aflibercept,
Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA) in 100 ll of
PBS or with vehicle (100 ll of PBS alone) intraperitoneally (i.p.) 2
and 4 days before tissue harvesting, as described (Ozawa et al, 2004).
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Anti-NRP1A antibody treatment
Animals were treated systemically by i.p. injection of the blocking
antibody anti-NRP1A (YW64.3, Genentech Inc., South San Francisco,
CA, USA) (Liang et al, 2007) in PBS with 0.5% BSA (10 mg/kg) at
the time of myoblast implantation (day 0) and after 3 and 6 days,
according to the previously published treatment schedule (Pan et al,
2007). IgG2a antibody (10 mg/kg in PBS with 0.5% BSA; Lubio
Science, Lucerne, Switzerland) was given i.p. as control.
Anti-TGF-b1 antibody treatment
Animals were treated systemically by i.p. injection of the specific
blocking antibody anti-TGF-b1 (Clone 9016, R&D Systems) in PBS
with 0.5% BSA (100 lg/animal/dose) at the time of myoblast
implantation (day 0) and after 2, 4, and 6 days, according to the
previously published treatment schedule (Wan et al, 2008). IgG1
antibody in PBS with 0.5% BSA (100 lg/animal/dose; R&D
Systems) was given i.p. as control.
Sema3A-Fc treatment
Tibialis anterior and Gastrocnemius muscles were injected 4 and
6 days after injection of myoblasts or adenoviral vectors with
Sema3A-Fc (R&D Systems) at a dose of either 0.1 or 10 mg/kg of
the average muscle weight (60 mg for Tibialis and 120 mg for
Gastrocnemius, corresponding to either 6 or 60 lg and 12 or 120 lg
of Sema3A-Fc per single injection, respectively) or equivalent
amounts of Fc fragment (Abcam, Cambridge, UK) in 15 ll of sterile
PBS with 0.5% BSA.
Tissue staining
Mice were anesthetized with ketamine (100 mg/kg) and xylazine
(10 mg/kg) and sacrificed by intravascular perfusion with 1%
paraformaldehyde in PBS pH 7.4. Tibialis anterior and Gastrocne-
mius muscles were harvested, post-fixed in 0.5% paraformaldehyde
in PBS for 2 h, cryoprotected in 30% sucrose in PBS overnight at
4°C, embedded in OCT compound (CellPath, Newtown, Powys,
UK), frozen in freezing isopentane, and cryosectioned. As areas of
effect were limited to the small portions of muscle corresponding to
the implantation sites, all analyses were performed on images taken
from the areas of engraftment, which were unequivocally identified
by tracking implanted myoblasts by X-gal staining (20-lm sections)
or adenoviral infection sites by the typical mononuclear infiltrate
with H&E (10-lm sections) in adjacent serial sections, as described
previously (Ozawa et al, 2004). Sections of 10 lm in thickness were
stained with the following primary antibodies and dilutions: rat
monoclonal anti-mouse CD31 (clone MEC 13.3, BD Biosciences,
Basel, Switzerland) at 1:100 or hamster monoclonal anti-mouse
CD31 (clone 2H8, Millipore, Merck, Germany) at 1:200; mouse
monoclonal anti-mouse a-SMA (clone 1A4, MP Biomedicals, Basel,
Switzerland) at 1:400; rabbit polyclonal anti-NG2 (Millipore) at
1:200; rat monoclonal anti-CD11b (clone M1/70, Abcam, Cambridge,
UK) at 1:100; rabbit polyclonal anti-NRP1 (Abcam) at 1:50; rabbit
polyclonal anti-p-SMAD2/3 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:100; and rabbit polyclonal anti-Sema3A (Abcam) at
1:50. Fluorescently labeled secondary antibodies (Invitrogen, Basel,
Switzerland) were used at 1:200. The Sema3A primary antibody was
detected with a biotinylated or with a peroxidase-labeled anti-rabbit
secondary antibody. The first chromogenic signal was developed
with Vectastain ABC kits (Vector Laboratories) and the Fast Red kit
(Dako, Baar, Switzerland), and the second with 3,30-diaminobenzidine-
tetrahydrochloride (Sigma).
To study vessel perfusion, 100 lg of fluorescein isothiocyanate
(FITC)-labeled Lycopersicon esculentum lectin in 50 ll (Vector Labo-
ratories) was injected into the femoral vein and allowed to circulate
for 4 min before intravascular perfusion with 1% paraformaldehyde
and leg muscle collection as described above.
RNA in situ hybridization (ISH)
Expression of Sema3A and CD31 mRNA was visualized in individual
cells in tissue sections with a highly sensitive and specific ISH
system, according to the manufacturer’s instructions (QuantiGene
ViewRNA, Affymetrix UK, High Wycombe, UK). Briefly, OCT-embed-
ded muscles were cryosectioned (10 lm thickness), mounted onto
Superfrost Plus Gold glass slides (Thermo Fischer Scientific, Wohlen,
Switzerland), and kept at 80°C until use. Slides were fixed with 4%
formaldehyde for 16–18 h at 4°C, washed, dehydrated in ethanol,
and pretreated by boiling for 1 min in pretreatment solution,
followed by 10-min digestion in Protease QF (both from Affymetrix).
Sections were hybridized for 2 h at 40°C with QuantiGene ViewRNA
probes specific for the mouse Sema3A and mouse CD31 RNA
sequences (VB1-11132-06 and VB6-12921-01, respectively, Affyme-
trix). For each experiment, one section was hybridized with probe
diluent only (Probe Set Diluent QT, Affymetrix) as negative control.
Label Probe oligonucleotides, conjugated to alkaline phosphatase
(LP-AP) type 1 or type 6, were added, followed by appropriate
substrates: an LP-AP type 6 probe was used with Fast Blue substrate
for Sema3A detection, followed by LP-AP type 1 probe with Fast Red
substrate for CD31 detection. Finally, slides were counterstained with
Meyer’s hematoxylin and DAPI and mounted with aqueous mounting
medium (Dako Ultramount Permanent Mounting Media S1964).
ISH image acquisition and quantification
The images were acquired with a laser scanning confocal microscope
(LSM710, Carl Zeiss Microscopy, Go¨ttingen, Germany) and Zen2
software (Carl Zeiss Microscopy). For each muscle section, the area
of injection was selected and high-power images (212.3 × 212.3 lm)
were acquired with a 40× objective. Pseudo-colors were assigned to
each fluorescent dye during acquisition (red for Fast Red, green for
Fast Blue and blue for DAPI). Color channels of the acquired images
were separated and exported as TIF files. Nuclei were identified by
DAPI staining. Red and green dots, corresponding to the staining
for CD31 and Sema3A mRNA, respectively, were identified and all
cells positive for either or both were counted manually in each field.
Histological analysis
Vessel length density (VLD) was quantified in fluorescently
immunostained cryosections as described (Ozawa et al, 2004).
Briefly, 10-15 fields per muscle (n = 4 muscles/group) were
analyzed by tracing the total length of vessels in the acquired field
and dividing it by the area of the fields. Vessel stabilization was
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calculated as the fraction of newly induced vessels, defined as the
amount of VLD in excess of the pre-existing VLD measured on
control uninjected muscles (VLD-ctrl), that survived after VEGF-
Trap treatment, according to the formula (VLD-Trap – VLD-ctrl)/
(VLD-vehicle – VLD-ctrl), where VLD-Trap = VLD after treatment
with VEGF-Trap and VLD-vehicle = VLD after treatment with vehi-
cle alone. All images were acquired using an Olympus BX61 micro-
scope (Olympus, Volketswil, Switzerland) and analyzed with Cell
Sense software (Olympus, Volketswil, Switzerland).
The quantification of vessel perfusion was performed on sections
of leg muscles harvested after intravascular staining with fluorescent
lectin, as described above. After co-staining with a fluorescent anti-
CD31 antibody, the total lengths of lectin-positive and CD31-positive
vascular structures in each field were traced and the vessel perfusion
index was calculated as the ratio between the two values.
The quantification of pericyte coverage was performed on
sections of leg muscles after immunostaining for endothelium (CD31)
and pericytes (NG2) as previously described (Li et al, 2011). Briefly,
the CD31- and NG2-positive areas were measured by ImageJ soft-
ware (http://rsb.info.nih.gov/ij/), and the pericyte coverage index
was calculated as the ratio between the two values (Li et al, 2011).
The quantification of CD11b+ cells was performed on sections of
leg muscles after immunostaining for endothelium (CD31) and
CD11b, and normalizing the absolute number of CD11b+ cells either
by vessel length or tissue area.
The immunohistochemistry staining for Sema3A was quantified as
reciprocal intensity by the standard intensity function in the
open source Fiji software (ImageJ) (http://fiji.sc/Fiji) as described
(Nguyen et al, 2013). Briefly, since the maximum intensity value of an
RGB image analyzed in ImageJ is 250, the intensity of a stained region
of interest was subtracted from 250, thereby deriving a reciprocal
intensity that is directly proportional to the amount of chromogen.
For vessel perfusion, pericyte coverage, CD11b+ cell frequency,
and Sema3A quantifications, 3–5 fields were analyzed in each
muscle (n = 4 muscles/group). All images were taken with a Carl
Zeiss LSM710 3-laser scanning confocal microscope (Carl Zeiss,
Feldbach, Switzerland) or Olympus BX61 microscope, and analyses
were conducted with Cell Sense software (Olympus).
No blinding was performed, but analyses were performed by two
independent investigators.
Ex vivo cell isolation by FACS
Pools of 20 limb muscles of SCID CB17 mice (Tibialis anterior and
Gastrocnemius) were harvested 7 days after myoblast injection and
processed as a single sample (n = 4–7 samples/group). Tissues were
minced, digested with DNase (0.2 mg/ml, Sigma-Aldrich), Collage-
nase type IV (484 U/ml, Worthington), Collagenase I (0.5 mg/ml;
Sigma-Aldrich), and Collagenase II (0.5 mg/ml, Sigma-Aldrich) in
low-glucose DMEM (Sigma-Aldrich) for 45 min at 37°C under
constant shaking, filtered through 100- and 70-lm cell strainers (BD
Biosciences), and washed twice in PBS. Cells were stained at 4°C
for 30 min with the following fluorescently labeled antibodies: PE-
anti-mouse CD31 (clone 390; BioLegend, San Diego, CA, USA) at
1:200; PE-Cy7-anti-mouse CD11b (clone M1/70, BioLegend) at
1:1,000. CD31+ and CD11b+ cells were isolated with an Influx cell
sorter (BD Biosciences). RNA was extracted, and gene expression
analysis was performed as described below.
In vitro endothelial cell assays
Mouse aortic endothelial cells (MAEC) were isolated as described
(Kobayashi et al, 2005) and cultured in high-glucose DMEM (Sigma-
Aldrich) supplemented with 10% FBS (HyClone, Logan, UT), 1 mM
sodium pyruvate, 0.1 mM MEM Non-Essential Amino Acids, 2 mM
glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin (Life
Technologies, Zug, Switzerland). 1 × 105 cells/well were seeded
into 24-well plates, cultured to confluence, and then stimulated with
recombinant mouse VEGF-A164 or human TGF-b1 (R&D Systems,
Abingdon, UK) at different concentrations (0, 1, 2.5, and 40 ng/ml)
in DMEM with 0.5% FBS at 37°C. After 24 h of stimulation, cells
were collected for RNA extraction (n = 4 samples/group).
Quantitative real-time PCR
For RNA extraction from total muscles, freshly harvested tissue was
disrupted using a Qiagen Tissue Lyser (Qiagen, Basel, Switzerland)
The paper explained
Problem
Vascular endothelial growth factor (VEGF) is the master regulator of
angiogenesis and its delivery is an attractive approach to grow new
blood vessels to treat ischemic diseases, an approach named thera-
peutic angiogenesis. A current challenge is that, while prolonged
expression is required to achieve persistence of newly induced vessels
and provide lasting therapeutic benefit, a short duration of treatment
is desirable to ensure safety, as sustained expression can cause
dysfunctional angiogenesis and the growth of angioma-like vascular
tumors. Therefore, there is a need to identify molecular targets to
accelerate vascular stabilization despite short-term VEGF delivery. To
address this need, here we investigated whether VEGF dose regulates
vascular stabilization and the underlying mechanism.
Results
Specific VEGF doses, in a therapeutically relevant range, were deliv-
ered to the clinical target tissue of skeletal muscle of mice, and VEGF
signaling was abrogated after 10 and 17 days by treatment with
Aflibercept, a receptor-body clinically approved for anti-VEGF therapy
in ophthalmology and oncology indications. Increasing VEGF doses
impaired vessel stabilization without affecting either pericyte coverage
or functional perfusion, but rather through a novel mechanism involv-
ing direct inhibition of the expression of the Neuropilin ligand
Semaphorin3A (Sema3A) by endothelium, leading to impaired recruit-
ment of Neuropilin-expressing monocytes (NEM) and reduced tissue
levels of transforming growth factor-b1 (TGF-b1). Interestingly, NEM
recruitment was amplified and maintained by a positive feedback
loop, whereby TGF-b1, secreted by Sema3A-recruited NEM, was
required to induce and maintain production of Sema3A by endothe-
lium. Blocking experiments showed that Sema3A signaling through
Neuropilin-1 was required to start the NEM/TGF-b1 axis. Conversely,
treatment with recombinant Sema3A rescued both NEM recruitment
and vascular stabilization impaired by increasing VEGF doses, and
enabled vessel persistence despite transient VEGF expression by clini-
cally relevant adenoviral vectors.
Impact
These findings suggest a strategy to achieve persistent new vascula-
ture despite limited duration of VEGF expression through co-delivery
of Sema3A and stimulation of NEM recruitment, thereby improving
the safety of therapeutic angiogenesis.
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in 1 ml TRIzol Reagent for 100 mg of tissue (Life Technologies).
Total RNA was isolated from lysed tissues, in vitro cultured MAEC
or ex vivo FACS-sorted cells with an RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instruction.
RNA from total muscles and MAEC was reverse-transcribed into
cDNA with the Omniscript Reverse Transcription kit (Qiagen) at
37°C for 60 min, whereas RNA from ex vivo sorted cells was
reverse-transcribed into cDNA with the Sensiscript RT kit (Qiagen).
Quantitative Real-Time PCR (qRT-PCR) was performed on an ABI
7300 Real-Time PCR system (Applied Biosystems). Expression of
genes of interest was determined using the following TaqMan gene
expression assays (Life Technologies): Pdgfb (Mm00440677_m1);
Tgfb1 (Mm01178820_m1); Ang1 (Mm0045603_m1); Ang2 (Mm0054
5822_m1); Sema3a (Mm00436469_m1); Id1 (Mm00775963_g1); and
Pai1 (Mm00435860_m1). Reactions were performed in triplicate for
each template, averaged, and normalized to expression of the Gapdh
housekeeping gene (Mm03302249_g1).
qRT–PCR was also performed on total genomic DNA to quantify
the number of myoblasts engrafted after implantation by measuring
the amount of stably integrated LacZ retroviral construct. A refer-
ence curve was constructed for each of the different myoblast clonal
populations with a 10-fold dilution series between 1 and 106 cells,
whereby the DCt data of each sample could be transformed into the
corresponding absolute cell numbers. LacZ primer and probe
sequences and reaction concentrations were previously published
(Mujagic et al, 2013).
Statistics
Data are presented as mean  standard error. The significance of
differences was assessed with the GraphPad Prism 6 software
(GraphPad Software). The normal distribution of all data sets was
tested, and, depending on the results, multiple comparisons were
performed with the parametric one-way analysis of variance
(ANOVA) followed by the Bonferroni test, or with the nonparametric
Kruskal–Wallis test followed by Dunn’s post-test. Gene expression
data representing fold-changes versus control, which are asymmetri-
cally distributed, were first normalized by logarithmic ln(y) transfor-
mation and then analyzed by one-way ANOVA followed by the
Bonferroni test for multiple comparisons, or by t-test with Welch’s
correction for single comparisons; P < 0.05 was considered statisti-
cally significant.
Animal studies
All animal studies were performed in accordance with the Swiss
Federal guidelines for animal welfare, after approval from the
Veterinary Office of the Canton of Basel-Stadt (Basel, Switzerland;
Permit 2071). Mice of 8–12 weeks of age, with equal representation
of both genders, were randomly assigned to experimental groups,
with a minimum of n = 4 mice/group.
Expanded View for this article is available online:
http://embomolmed.embopress.org
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Expanded View Figures
A
B
Figure EV1. Vessels induced by different VEGF doses are similarly
perfused.
Mice received intravenous injections of FITC-lectin 2 weeks after implantation of
myoblast clones expressing different VEGF levels.
A Frozen sections of limb muscles were immunostained for CD31
(endothelium, in red) and perfused structures were visualized by FITC-lectin
co-localization (in green). Scale bar = 50 lm.
B Quantification of the perfusion index (lectin-positive vessel length/CD31-
positive vessel length) showed that both normal capillaries and aberrant
structures induced by the different VEGF doses were similarly perfused.
Data represent the mean  SEM of individual images (n) acquired from
three muscles/group: Ctrl, n = 3; V Low, n = 8; V Med, n = 8; V High, n = 7.
Data were subjected to Kruskal–Wallis analysis with Dunn’s multiple
comparisons test and no significant differences were detected.
Source data are available online for this figure.
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Figure EV2. Mononuclear cells recruited to the
sites of VEGF-induced neovascularization express
both CD11b and NRP1.
A Immunofluorescence staining for CD11b (in red)
and NRP1 (in green) on frozen sections from
muscles 1 week after implantation of V Low-,
V Med-, and V High-expressing myoblast clones
or control cells (Ctrl). Essentially all CD11b-
positive cells also expressed NRP1. Nuclei positive
for NRP1, but not for CD11b, belong to
endothelial cells. Scale bar = 25 lm.
B Flow cytometry analysis confirmed that CD11b-
positive monocytes isolated from the muscles
implanted with VEGF-expressing cells were also
NRP1-positive. The panels show representative
data from two independent experiments.
Figure EV3. Ex vivo purified NEM express higher levels of TGF-b1 than
endothelial cells.
TGF-b1 gene expression was quantified on NEM (CD11b) and endothelial cells
(CD31) FACS-purified from muscles 1 week after implantation with V Low-,
V Med-, and V High-expressing myoblast clones. The expression in CD11b-
positive cells is shown as fold-change versus that in endothelial cells. Data
represent individual values, with mean  SEM (n = 4–7); *P < 0.05 by t-test
withWelch’s correction: V Low— CD11b versus CD31 P = 0.0315; V High—CD11b
versus CD31 P = 0.0281.
Source data are available online for this figure.
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Figure EV4. Expression of the TGF-b1
downstream genes Id-1 and PAI-1 is not
stimulated by VEGF.
A–D Mouse aortic endothelial cells were stimulated
in vitro with increasing doses of recombinant
VEGF164 or TGF-b1 for 24 h. The expression of
Id-1 and PAI-1 was quantified by qRT–PCR and
expressed as fold-change versus that of non-
stimulated cells. Increasing VEGF doses did not
significantly change Id-1 (A) and PAI-1
expression (B), whereas TGF-b1 upregulated
both (C, D). Data represent individual values,
with mean  SEM (n = 2–4); *P < 0.05,
**P < 0.01, and ***P < 0.001 by one-way
ANOVA with Bonferroni multiple comparisons
test, after data normalization by logarithmic
transformation; Id-1 and PAI-1 expression
upon VEGF stimulation: no significant
differences were detected; Id-1 expression
upon TGF-b1 stimulation: 10 versus 0
P = 0.0058; 0 versus 40 P = 0.0247; PAI-1
expression upon TGF-b1 stimulation: all
comparisons versus 0 P < 0.0001.
Source data are available online for this figure.
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